TDOC · Teladoc Health, Inc.

The thesis

Teladoc Health's Q3 2026 report beat on revenue and earnings, but BetterHelp's paying users fell to 0.336 million and the company guided BetterHelp's Q4 revenue down 18.5% to 31.5%, so the turnaround remains unproven. The shares closed at $6.88 on 28 October 2026, before the report, and the Q4 BetterHelp result decides whether the decline is ending.

Teladoc reported Q3 revenue of $605.1 million, down 3% year over year, per its 28 October 2026 results release. Benzinga put the consensus estimate at $588.5 million. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted for items the company excludes) was $79.4 million, up 14%, above the $62–74 million guided on 29 July 2026.

The narrative is maturing: the story is well known, and the 28 October 2026 report gave the first new financial numbers since the 29 July 2026 guidance cut. The beat sits next to a steeper BetterHelp guide, which keeps the case unproven.

Bullish and bearish views on Teladoc Health, Inc.

The bull case on Teladoc Health, Inc. (TDOC), in brief: Revenue and profit beat guidance. The bear case: BetterHelp paying users fell again.

Bull case

• Revenue and profit beat guidance. Q3 revenue of $605.1 million cleared the $569–609 million guide, and net loss was $26.9 million, or $0.15 per share, against a $0.21 loss expected, per Benzinga on 28 October 2026.
• Full-year ranges were narrowed upward at the floor. FY2026 revenue guidance moved to $2,395–2,441 million from $2,362–2,447 million. Free-cash-flow guidance is $135–165 million, narrowed from $130–170 million, per the 28 October 2026 release.
• Cash generation improved. Q3 free cash flow was $75.9 million versus $67.9 million a year earlier.
• Integrated Care keeps growing. Segment revenue was $398.5 million in Q3, up 2% year over year, versus 1% growth in Q2 2026.
• Insurance reach is broad. BetterHelp's 9 September 2026 release cited relationships with more than 125 health plans covering more than 150 million contracted lives.

Bear case

• BetterHelp paying users fell again. Average paying users were 0.336 million in Q3, against 0.346 million in Q2 2026 and 0.382 million a year earlier. The 15 October 2026 note named 0.346 million as the level to hold.
• BetterHelp revenue is guided lower still. Q3 BetterHelp revenue was $206.6 million, down 13%. Q4 BetterHelp revenue growth is guided at negative 31.5% to negative 18.5%, versus negative 16.1% to negative 12.9% for the full year, per the 28 October 2026 release.
• Q4 guidance spans a wide range. Q4 revenue is guided at $569–615 million against a $597.4 million consensus estimate, per Benzinga on 28 October 2026.
• Nine-month cash flow trails last year. Free cash flow was $85.4 million for the first nine months of 2026, against $113.5 million a year earlier.
• Management turnover continues. Michael Grasher became chief financial officer on 31 August 2026. Press reports say the chief legal officer steps down in early November.
• Analyst targets are stale. Consensus rating is Hold with a $7.68 average target, per Bullstory on 28 September 2026. Citigroup's target is $8 and BMO Capital's is $5.50. Revisions after the 28 October 2026 report were not yet visible.

Price setup

The adjusted close was $6.88 on 28 October 2026, 29.2% below the 52-week high of $9.72. The close was $5.52 on 2 October 2026 and $5.97 on 15 October 2026. The 14-day Relative Strength Index (a 0–100 gauge of recent buying and selling pressure) was 76.6 on 28 October 2026, against 16.4 on 2 October 2026. The shares are up 2.5% over three months.

Benzinga reported the shares rising in after-market trading on 28 October 2026 after the results. The size of that move is not in the sources reviewed, so the first regular-session close after the report is the reference.

Crowding evidence: the 14-day Relative Strength Index above 70 shows a fast run from the early-October low, and the earnings date has now passed. No Form 4 insider sales or share issuance are in the sources reviewed.

Catalysts, next 30 days

• ~29 October to 5 November 2026 (est.): analyst target revisions. Citigroup's $8 and BMO's $5.50 sit around the pre-report price.
• ~3 November 2026 (est.): chief legal officer departure. Press reports place it in early November.
• ~5 November 2026 (est.): Form 10-Q for Q3. It may add BetterHelp insurance-mix detail behind the paying-user decline.
• ~2027-02 (est.): Q4 2026 report. It tests the BetterHelp guide of negative 31.5% to negative 18.5%.

Elapsed catalysts

• 29 October 2026: first regular session after the report. It shows how the market weighs the beat against the Q4 BetterHelp guide. (passed 2d ago)

What would change the view

The case breaks if BetterHelp revenue tracks the weak end of the Q4 guide and a later report cuts FY2026 free-cash-flow guidance below $135 million or revenue guidance below $2,395 million. Paying users below 0.336 million at the next report would confirm the decline is still running.

The case improves if BetterHelp's Q4 revenue lands at or above the negative 18.5% end of its guide and paying users stop falling from 0.336 million. A daily close below $5.50 would put the shares under the 2 October 2026 close of $5.52 and end the case.

What it trades with

Teladoc trades on its own company evidence: BetterHelp user trends, insurance reimbursement and cash flow. No current theme cluster carries the name. Integrated Care is a hospital and health-system business, so enterprise health-care spending affects it more than consumer therapy demand does. BetterHelp's cash-pay revenue depends on consumer marketing efficiency and on how AI mental-health tools change demand; OpenAI's 23 September 2026 MentalHealthBench release contained no Teladoc-specific result.